Cover Image
市場調查報告書

Astellas Pharma Inc. - 產品平台分析

Astellas Pharma Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224547
出版日期 內容資訊 英文 285 Pages
訂單完成後即時交付
價格
Back to Top
Astellas Pharma Inc. - 產品平台分析 Astellas Pharma Inc. - Product Pipeline Review - 2016
出版日期: 2016年05月31日 內容資訊: 英文 285 Pages
簡介

Astellas Pharma Inc.是代表日本的全球性製藥公司之一,致力於廣大領域的醫藥品之研究開發及產品化。該公司的產品主要由泌尿科,移植,免疫力缺乏,感染疾病,癌,神經科學,代謝性疾病等領域的市售品或開發中產品構成。

本報告提供Astellas Pharma Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Astellas Pharma Inc.的基本資料

  • Astellas Pharma Inc.概要
  • 主要資訊
  • 企業資料

Astellas Pharma Inc.:R&D概要

  • 主要的治療範圍

Astellas Pharma Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Astellas Pharma Inc.:開發中產品概況

  • 最後階段的開發中產品
  • 臨床實驗階段的開發中產品
  • 初期階段的開發中產品

Astellas Pharma Inc.:藥物簡介

  • capsaicin
  • evolocumab
  • tacrolimus ER
  • (mirabegron + solifenacin succinate)
  • amenamevir
  • ASP-0113
  • bendamustine hydrochloride
  • degarelix acetate
  • enzalutamide
  • fidaxomicin
  • gilteritinib fumarate
  • linaclotide
  • peficitinib hydrobromide
  • quetiapine fumarate ER
  • romosozumab
  • roxadustat
  • solifenacin succinate
  • ASP-1707
  • ASP-3662
  • ASP-8232
  • ASP-8273
  • ASP-8477
  • erlotinib hydrochloride
  • FG-2216
  • ipragliflozin
  • regadenoson
  • linsitinib
  • AGS-16C3F
  • AGS-67E
  • ASG-15ME
  • ASP-2205
  • ASP-2905
  • ASP-3325
  • ASP-4132
  • ASP-4345
  • ASP-5094
  • ASP-5633
  • ASP-5878
  • ASP-6282
  • ASP-6858
  • ASP-7962
  • enfortumab vedotin
  • mirabegron ER
  • OSI-930
  • AS-1069562
  • AS-1535907
  • AS-1669058
  • AS-1708727
  • AS-1940477
  • AS-2034178
  • AS-2077715
  • AS-2444697
  • AS-2521780
  • AS-2575959
  • AS-2690168
  • AS-2715348
  • AS-2795440
  • AS-288640100
  • ASP-1017
  • ASP-1645
  • ASP-3258
  • ASP-5736
  • ASP-6537
  • ASP-7663
  • ASP-9133
  • ASP-9726
  • FK-886
  • KB-425796C
  • Monoclonal Antibodies for Infectious Diseases
  • Monoclonal Antibody Conjugates for Oncology
  • OSI-296
  • respiratory syncytial virus vaccine
  • Small Molecule 2 for Epilepsy
  • Small Molecule 3 for Epilepsy
  • Small Molecule 4 for Epilepsy
  • Small Molecule for Epilepsy
  • Small Molecule to Antagonize IGF-1 Receptor for Colorectal Cancer
  • Small Molecule to Block N-type Calcium Channels for Neuropathic Pain
  • Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer
  • Small Molecule to Inhibit JAK3 for Transplantation
  • Small Molecule to Inhibit PDE10A for Schizophrenia
  • Small Molecule to Inhibit TAK1 for Ovarian Cancer
  • Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes
  • Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine
  • Small Molecules to Inhibit DAAO for Cognitive Disorders
  • Small Molecules to Inhibit RANKL for Osteoclastogenesis
  • Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema
  • AS-1468240
  • Drug For Alzheimer's Disease
  • Drugs for Pancreatic Cancer
  • KB-425796A
  • Monoclonal Antibodies for Cancer
  • Small Molecules For Neglected Tropical Diseases
  • Small Molecules for Non-Neuromuscular and Neuromuscular Disorders
  • Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders
  • Small Molecules to Inhibit ACK1 for Cancer

Astellas Pharma Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Astellas Pharma Inc.:最近的開發平台趨勢

Astellas Pharma Inc.:暫停中的計劃

Astellas Pharma Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介

Astellas Pharma Inc.:企業發表

Astellas Pharma Inc.:總公司和子公司的所在地

Astellas Pharma Inc.:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08058CDB

Summary

Global Markets Direct's, 'Astellas Pharma Inc. - Product Pipeline Review - 2016', provides an overview of the Astellas Pharma Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Astellas Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Astellas Pharma Inc.
  • The report provides overview of Astellas Pharma Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Astellas Pharma Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Astellas Pharma Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Astellas Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Astellas Pharma Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Astellas Pharma Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Astellas Pharma Inc. Snapshot
    • Astellas Pharma Inc. Overview
    • Key Information
    • Key Facts
  • Astellas Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Astellas Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Astellas Pharma Inc. - Pipeline Products Glance
  • Astellas Pharma Inc. - Late Stage Pipeline Products
  • Astellas Pharma Inc. - Clinical Stage Pipeline Products
  • Astellas Pharma Inc. - Early Stage Pipeline Products
  • Astellas Pharma Inc. - Drug Profiles
    • linaclotide
    • solifenacin succinate
    • tacrolimus ER
    • (ipragliflozin + sitagliptin phosphate)
    • (mirabegron + solifenacin succinate)
    • amenamevir
    • ASP-0113
    • bendamustine hydrochloride
    • degarelix acetate
    • enzalutamide
    • evolocumab
    • fidaxomicin
    • gilteritinib fumarate
    • mirabegron ER
    • naquotinib mesylate
    • peficitinib hydrobromide
    • quetiapine fumarate ER
    • romosozumab
    • roxadustat
    • AGS-16C3F
    • ASP-1707
    • ASP-3662
    • ASP-7962
    • ASP-8232
    • erlotinib hydrochloride
    • FG-2216
    • ipragliflozin
    • linsitinib
    • MA09-hRPE
    • regadenoson
    • blinatumomab
    • AGS-67E
    • ASG-15ME
    • ASP-0819
    • ASP-2205
    • ASP-2905
    • ASP-4132
    • ASP-4345
    • ASP-5094
    • ASP-5878
    • ASP-6282
    • ASP-6294
    • ASP-7266
    • ASP-7398
    • ASP-8062
    • enfortumab vedotin
    • OSI-930
    • AS-1069562
    • AS-1669058
    • AS-1940477
    • AS-2034178
    • AS-2077715
    • AS-2444697
    • AS-2521780
    • AS-2575959
    • AS-2715348
    • AS-2795440
    • AS-288640100
    • ASP-1017
    • ASP-1645
    • ASP-3258
    • ASP-5736
    • ASP-6537
    • ASP-7663
    • ASP-9133
    • ASP-9726
    • FK-886
    • Gene Therapy to Activate mVChR1 for Retinits Pigmentosa
    • KB-425796C
    • Monoclonal Antibody Conjugates for Oncology
    • OSI-296
    • Small Molecule 2 for Epilepsy
    • Small Molecule 3 for Epilepsy
    • Small Molecule 4 for Epilepsy
    • Small Molecule for Epilepsy
    • Small Molecule to Block N-type Calcium and hERG Potassium Channels for Neuropathic Pain
    • Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer
    • Small Molecule to Inhibit JAK3 for Heart Transplantation
    • Small Molecule to Inhibit PDE10A for Schizophrenia
    • Small Molecule to Inhibit TAK1 for Ovarian Cancer
    • Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes
    • Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine
    • Small Molecules to Inhibit DAAO for Cognitive Disorders
    • Small Molecules to Inhibit RANKL for Osteoclastogenesis
    • Stem Cell Therapy for Autoimmune Diseases
    • Stem Cell Therapy for Corneal Blindness
    • Stem Cell Therapy for Glaucoma
    • Stem Cell Therapy for Ophthalmic Disorders
    • UMN-0901
    • AS-1468240
    • Drugs for Pancreatic Cancer
    • KB-425796A
    • Monoclonal Antibodies for Oncology
    • Small Molecules for Non-Neuromuscular and Neuromuscular Disorders
    • Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders
    • Small Molecules to Inhibit ACK1 for Oncology
  • Astellas Pharma Inc. - Pipeline Analysis
    • Astellas Pharma Inc. - Pipeline Products by Target
    • Astellas Pharma Inc. - Pipeline Products by Route of Administration
    • Astellas Pharma Inc. - Pipeline Products by Molecule Type
    • Astellas Pharma Inc. - Pipeline Products by Mechanism of Action
  • Astellas Pharma Inc. - Recent Pipeline Updates
  • Astellas Pharma Inc. - Dormant Projects
  • Astellas Pharma Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Astellas Pharma Inc. - Company Statement
  • Astellas Pharma Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Astellas Pharma Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Astellas Pharma Inc., Key Information
  • Astellas Pharma Inc., Key Facts
  • Astellas Pharma Inc. - Pipeline by Indication, 2016
  • Astellas Pharma Inc. - Pipeline by Stage of Development, 2016
  • Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Astellas Pharma Inc. - Partnered Products in Pipeline, 2016
  • Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016
  • Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Astellas Pharma Inc. - Pre-Registration, 2016
  • Astellas Pharma Inc. - Filing rejected/Withdrawn, 2016
  • Astellas Pharma Inc. - Phase III, 2016
  • Astellas Pharma Inc. - Phase II, 2016
  • Astellas Pharma Inc. - Phase I, 2016
  • Astellas Pharma Inc. - IND/CTA Filed, 2016
  • Astellas Pharma Inc. - Preclinical, 2016
  • Astellas Pharma Inc. - Discovery, 2016
  • Astellas Pharma Inc. - Pipeline by Target, 2016
  • Astellas Pharma Inc. - Pipeline by Route of Administration, 2016
  • Astellas Pharma Inc. - Pipeline by Molecule Type, 2016
  • Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2016
  • Astellas Pharma Inc. - Recent Pipeline Updates, 2016
  • Astellas Pharma Inc. - Dormant Developmental Projects,2016
  • Astellas Pharma Inc. - Discontinued Pipeline Products, 2016
  • Astellas Pharma Inc., Other Locations
  • Astellas Pharma Inc., Subsidiaries
  • Astellas Pharma Inc., Key Manufacturing Facilities

List of Figures

  • Astellas Pharma Inc. - Pipeline by Top 10 Indication, 2016
  • Astellas Pharma Inc. - Pipeline by Stage of Development, 2016
  • Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • Astellas Pharma Inc. - Partnered Products in Pipeline, 2016
  • Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2016
  • Astellas Pharma Inc. - Pipeline by Top 10 Target, 2016
  • Astellas Pharma Inc. - Pipeline by Route of Administration, 2016
  • Astellas Pharma Inc. - Pipeline by Molecule Type, 2016
  • Astellas Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top